13 Jul 2024

Press & news

FluoGuide develops surgical solutions that is expected to reduce suffering for the patient and increases the likelihood of cure as well as reducing costs for the health care system.

New - New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

Member of the board of directors Shomit Ghose sells 3000 shares

Press release

September 27, 2021

Copenhagen, Denmark, 27 September 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) today announces that Shomit Ghose (board member) has sold shares to pay income tax on his shareholdings in FluoGuide due to U.S. tax regulations.

Shomit Ghose has on the 24 September sold 3,000 shares to an price of 92,81 SEK per share.

“Due to the success of FluoGuide, I have to pay tax on my shareholdings of FluoGuide and I have decided to finance this by selling some of my shares in FluoGuide”, says Shomit Ghose, member of the Board of Directors of FluoGuide and continues: “I have a strong confidence in FluoGuide with a visionary leadership, promising technology and execution power I have rarely seen even compared to a U.S. standard. I am very proud to be part of its exciting development and committed to contribute to fully utilizing FluoGuide’s data utilization potential in advance surgical guidance.”

The transactions are reported to The Danish Financial Supervisory Authority (Danish: “Finanstilsynet”) in accordance with current regulations.

For more information please contact:

Morten Albrechtsen, CEO
FluoGuide A/S
Phone: +45 24 25 62 66

 Certified Adviser:

Svensk Kapitalmarknadsgransking AB
Phone: +46 70 755 95 51

 About FluoGuide

FluoGuide’s primary focus is to maximize surgical outcomes in oncology. The Company’s lead product, FG001, is designed to improve surgical precision by illuminating cancer cells intraoperatively. The improved precision enabled by FluoGuide’s products has a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, the improved precision will improve a patient’s chance of achieving a complete cure and will lower system-wide healthcare costs. The Company is conducting a proof-of-concept clinical study (phase I/II) to demonstrate the effect of FG001 in patients with high grade glioma. FluoGuide is listed on Nasdaq First North Sweden under the ticker “FLUO”.